Product Information
CRESTOR 40 MG TABLET is a brand product labeled by AstraZeneca Pharmaceuticals LP, priced at $8.8066 per EA under NDC 00310759030. Its NADAC has been published 185 times since Mar 9, 2022.
FDA first approved this application on Aug 12, 2003. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the Rosuvastatin market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
40 mg/1
Manufacturer
AstraZeneca Pharmaceuticals LPNDC
00310759030
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ROSUVASTATIN CALCIUMApproval Type
New Drug (NDA)
FDA Application
NDA021366FDA Approved
8/12/2003
TE Code
AB
On Market Since
1/24/2022
Pharmacological Classes
Price Statistics
The NADAC for CRESTOR 40 MG TABLET has been published 185 times since Mar 9, 2022, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $8.8066 per EA |
|---|---|
| All-time high | $8.8505 (Jun 15, 2022) |
| All-time low | $8.8063 (Aug 19, 2026) |
| 52-week high | $8.8313 |
| 52-week low | $8.8063 |
| Median price | $8.8259 |
| Average price | $8.8256 |
| Largest weekly change | -0.5% (Jun 22, 2022) |
| Weeks tracked | 185 |
| Tracking since | Mar 9, 2022 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 99% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
AstraZeneca Pharmaceuticals LP manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Rosuvastatin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
HMG-CoA Reductase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CRESTOR 40 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for CRESTOR 40 MG TABLET, manufactured by AstraZeneca Pharmaceuticals LP, is $8.8066 per EA (NDC 00310759030), effective Sep 30, 2026.
How has the price of CRESTOR 40 MG TABLET changed over time?
Over the history we have for it, the NADAC for CRESTOR 40 MG TABLET has held within roughly two percent of its current level. It has been tracked across 185 weekly CMS publications since Mar 9, 2022.
What are the highest and lowest recorded NADAC prices for CRESTOR 40 MG TABLET?
Since Mar 9, 2022, the NADAC for CRESTOR 40 MG TABLET has ranged from a low of $8.8063 (Aug 19, 2026) to a high of $8.8505 (Jun 15, 2022), with a median of $8.8259 per EA.
Are there cheaper alternatives to CRESTOR 40 MG TABLET?
Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ROSUVASTATIN CALCIUM 40 MG TAB, is $0.0621 per EA — about 99% below CRESTOR 40 MG TABLET.
Who manufactures CRESTOR 40 MG TABLET?
CRESTOR 40 MG TABLET (NDC 00310759030) is labeled by AstraZeneca Pharmaceuticals LP, and CMS classifies it as a brand product.